NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
$2.19
-$0.69(-14.70%)
At close: 4:00 PM EST
$2.19
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.58 - $3.84
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$72.42M
Enterprise Value$30.69M
Total Cash (Recent Filing)$7.80M
Total Debt (Recent Filing)$631.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 19, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding33,067,630
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue25.05
Enterprise Value/Gross Profit49.50
Enterprise Value/Ebitda-0.92
Forecast
1Y Price Target
$39.33Price Target Upside1695.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.69
Revenue Forecast (FY)$112.79M
Bulls Say, Bears Say
Bulls Say
Manufacturing CapabilityAcceptance of the KETAFREE application, confirmed commercial registration batches, and scalable domestic production position the company to address U.S. ketamine shortages and support product launch.
Real-world EvidenceA real‑world dataset covering more than 65,000 patients strengthens the submission package for NRX-100 and reduces reliance on new clinical trials to demonstrate safety and effectiveness.
Regulatory PathwayFDA indicated willingness to review a combined package of prior controlled trials plus a real‑world dataset, creating a clear Fast Track pathway to file a New Drug Application for NRX-100.
Bears Say
Clinical Network ScalingHOPE network remains in an early growth stage with only a few owned centers, creating execution and scaling risk that could delay clinic‑driven revenue and patient access expansion.
Financial RunwayReported operating and net losses combined with relatively limited cash on hand create funding and runway risk that could require dilutive financing or constrain operations.
Revenue And Guidance ShortfallReported revenue and net loss below analyst and consensus expectations, together with absence of financial guidance, raise uncertainty about near‑term business momentum.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.58 and its highest was $3.84 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $72.42M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is May 19, 2026 which is in 52 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Mar 24, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.007 by -$0.047.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is 0.31.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 33,067,630 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.007. Following the earnings report the stock price went up 20.339%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.33 (1695.89% Upside)
$39.33 (1695.89% Upside)
Hedge Fund Trend
Decreased
By 50.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
138.71%
Trailing 12-Months
Asset Growth
236.08%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRXP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated multiple concrete regulatory, manufacturing and commercialization milestones (preliminary bioequivalence for KETAFREE, FDA openness to RWE for NRX-100, expanded Fast Track, manufactured registration batches, >25,000 NRX-101 doses, EBITDA-positive acquired clinics, and expense reductions). These highlights show tangible progress toward near-term approvals and commercial scale-up. Offsetting risks include a modest cash balance ($7.8M) with an ongoing $16.2M operating loss, early-stage clinic revenues, remaining regulatory steps and formulation/clinical validation needs for the D-cycloserine program. On balance the company presented more substantive positive catalysts and de-risking actions than unresolved negatives, but execution and financing risks remain material.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$39.33
▲(1695.89% Upside)
Technical Analysis
CervoMed
―
Coeptis Therapeutics Holdings
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
11.84%
Insiders
2.48% Mutual Funds
11.26% Other Institutional Investors
70.75% Public Companies and Individual Investors